tiprankstipranks
Trending News
More News >
Global Health Clinics (TSE:MJRX)
:MJRX

Global Health Clinics (MJRX) AI Stock Analysis

Compare
0 Followers

Top Page

TSE:MJRX

Global Health Clinics

(MJRX)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - 5.2)
Rating:46Neutral
Price Target:
C$0.05
▲(145.00% Upside)
The score is primarily constrained by very weak financial performance—shrinking revenue, deeply negative margins, ongoing cash burn, and a highly stressed balance sheet with negative equity. Technicals provide a partial offset with the price above major moving averages and moderate momentum, but valuation remains unattractive due to losses (negative P/E) and no dividend yield data.

Global Health Clinics (MJRX) vs. iShares MSCI Canada ETF (EWC)

Global Health Clinics Business Overview & Revenue Model

Company DescriptionGlobal Health Clinics Ltd. operates in the cannabis industry. The company operates medical clinics, which guide patients through the process of becoming legal users of marijuana. It also engages in developing psilocybin products for research and usage for pharmaceutical purposes. The company was formerly known as Leo Resources Inc. and changed its name to Global Health Clinics Ltd. in August 2018. Global Health Clinics Ltd. was incorporated in 2013 and is headquartered in Vancouver, Canada.
How the Company Makes MoneyGlobal Health Clinics (MJRX) generates revenue primarily through the provision of healthcare services at its clinics. Patients pay for medical consultations, treatments, and health programs either directly or through insurance reimbursements. Additionally, the company may earn income from partnerships with healthcare providers and wellness product suppliers, as well as from offering specialized health programs that could have subscription-based models. The ability to attract and retain patients, as well as maintaining partnerships with insurance companies and healthcare providers, are crucial factors contributing to MJRX's earnings.

Global Health Clinics Financial Statement Overview

Summary
Global Health Clinics is in a precarious financial state, characterized by continuous losses, high leverage, and negative equity. Revenue and cash flow trends are deteriorating, suggesting significant operational and financial restructuring is needed to achieve stability. The company's current trajectory poses substantial risks to future viability.
Income Statement
9
Very Negative
The company's income statement reveals significant financial distress, with consistent negative net income and declining revenue trends. The gross profit margin is relatively healthy, but the net profit margin is severely negative due to high operating losses. Revenue has shown a negative growth trajectory, exacerbating financial challenges.
Balance Sheet
6
Very Negative
The balance sheet indicates severe financial instability with negative stockholders' equity, high debt levels, and a negative equity ratio. The debt-to-equity ratio is undefined due to negative equity, highlighting extreme leverage and potential insolvency risks. Asset levels are quite low compared to liabilities, underscoring financial vulnerability.
Cash Flow
12
Very Negative
Cash flow analysis shows persistent negative operating and free cash flows, reflecting ongoing liquidity issues. The operating cash flow to net income ratio is negative, indicating insufficient cash generation relative to losses. The company relies heavily on financing activities to cover cash outflows, which is unsustainable in the long term.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue47.77K82.96K102.85K146.81K225.09K
Gross Profit-515.73K63.88K80.64K116.00K177.75K
EBITDA-1.05M-947.00K-1.57M-1.35M-8.34M
Net Income-1.27M-1.08M-1.63M-1.37M-8.48M
Balance Sheet
Total Assets66.14K29.33K241.50K578.81K610.60K
Cash, Cash Equivalents and Short-Term Investments50.48K9.19K214.34K496.69K456.26K
Total Debt1.91M1.52M1.10M322.31K30.81K
Total Liabilities4.59M3.29M2.43M1.14M1.05M
Stockholders Equity-4.53M-3.26M-2.18M-559.58K-440.39K
Cash Flow
Free Cash Flow-572.21K-496.55K-1.01M-1.49M-825.80K
Operating Cash Flow-572.21K-496.55K-1.01M-1.49M-825.80K
Investing Cash Flow0.000.000.000.00428.97K
Financing Cash Flow613.50K291.40K727.48K1.53M763.22K

Global Health Clinics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.02
Price Trends
50DMA
0.04
Negative
100DMA
0.02
Positive
200DMA
0.02
Positive
Market Momentum
MACD
>-0.01
Positive
RSI
47.05
Neutral
STOCH
6.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MJRX, the sentiment is Neutral. The current price of 0.02 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and above the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.05 is Neutral, neither overbought nor oversold. The STOCH value of 6.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:MJRX.

Global Health Clinics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
C$2.71B45.252.42%6.18%-28.69%
60
Neutral
C$2.37B-12.65-9.95%4.27%3.41%
59
Neutral
C$886.96M-12.38-10.92%3.56%-0.94%-540.90%
58
Neutral
C$2.96B-7.86-27.61%-3.38%-31.35%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
C$2.17B-4.68-33.01%-4.58%-141.91%
46
Neutral
C$281.76K-0.21-42.42%-17.33%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:MJRX
Global Health Clinics
0.03
0.02
200.00%
TSE:CURA
Curaleaf Holdings
3.83
1.87
95.41%
TSE:GTII
Green Thumb Industries
11.68
1.31
12.63%
TSE:TRUL
Trulieve Cannabis
12.40
5.34
75.64%
TSE:VRNO
Verano Holdings
6.32
0.00
0.00%
TSE:DHT.UN
DRI Healthcare
16.11
4.41
37.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 30, 2025